Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Conditions:   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma Intervention:   Combination Product: CD19 CART Sponsors:   Chinese PLA General Hospital;   Shenzhen University;   Shenzhen University General Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials